Ziltivekimab Stumbles in ZEUS: Novo Nordisk's Cardiovascular Outcomes Trial Misses Mark

summarizeSummary

Novo Nordisk's ZEUS phase 3 trial of ziltivekimab failed to meet its primary endpoint of reducing cardiovascular events in high-risk patients, a notable pipeline disappointment that will trigger a non-cash impairment charge in Q3 2026.

check_boxKey Events · Product Development and Regulatory · NVO

• ZEUS Trial Misses Primary Endpoint

  Ziltivekimab showed no reduction in MACE vs placebo (HR 0.99, 95% CI 0.88–1.11) in over 6,300 patients with ASCVD, CKD, and inflammation.

• Non-Cash Impairment Charge Expected

  Novo Nordisk will record a non-cash impairment charge in Q3 2026 related to the ZEUS failure, though the 2026 adjusted operating profit outlook is unchanged.

• Two Other Ziltivekimab Trials Continue

  The HERMES (heart failure) and ARTEMIS (post-heart attack) trials are ongoing, with readouts anticipated in the first half of 2027.

• Safety Profile Consistent with IL-6 Inhibition

  Serious infections were higher with ziltivekimab, consistent with its mechanism; overall adverse events were similar to placebo, with no difference in all-cause mortality.

auto_awesomeAnalysis · NVO · Life Sciences

In a significant setback for its cardiovascular pipeline, the ZEUS phase 3 trial—which enrolled over 6,300 patients with ASCVD, CKD, and inflammation—failed to show that ziltivekimab reduced major adverse cardiovascular events compared to placebo, yielding a hazard ratio of 0.99. While the 2026 profit outlook remains intact, the miss will trigger a non-cash impairment charge in Q3 2026. Two additional ziltivekimab studies, HERMES in heart failure and ARTEMIS in post-heart attack patients, are still underway, with data expected in the first half of 2027.